Services on Demand
Journal
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
- uBio
Share
Acta bioquímica clínica latinoamericana
Print version ISSN 0325-2957On-line version ISSN 1851-6114
Abstract
LUCERO, Diego et al. Adiponectin would determine the predominance of altered VLDL in metabolic syndrome. Acta bioquím. clín. latinoam. [online]. 2016, vol.50, n.4, pp.575-581. ISSN 0325-2957.
The aim of the work was to evaluate whether the reduction of adiponectin (ADP) in metabolic syndrome (MetS) affects the atherogenic features of VLDL. A total of 45 patients with MetS (ATPIII) and 15 healthy controls were studied. In fasting serum, lipid profile, free fatty acids (FFA) and ADP were determined. VLDL was isolated (d<1.006 g/L) and characterized in chemical composition and size (size exclusion-HPLC). In post-heparin plasma, lipoprotein lipase (LPL) activity was measured. In MetS, VLDL showed increased total mass, particle number, VLDL-triglyceride content and higher large-VLDL proportion (p<0.05). The increase in FFA correlated with VLDL mass (r=0.36; p=0.009), VLDL particle number (r=0.45; p=0.0006) and large-VLDL proportion (r=0.32; p=0.02). MetS patients showed a decrease in ADP (7.4±4.8 vs. 15.5±7.2 μg/mL, p=0.01) and in LPL activity (p=0.01), that positively correlated between them (r=0.38; p=0.01; adjusted by HOMA-IR and waist: β=0.35; p=0.02). ADP inversely correlated with FFA and large-VLDL% (p<0.03). It can be concluded that in MetS, decreased ADP would favour the secretion of triglyceride over-enriched and larger VLDL particles, and also would delay VLDL catabolism mediated by LPL, resulting in the accumulation of altered VLDL with atherogenic characteristics.
Keywords : Metabolic syndrome; Adiponectin; VLDL-triglycerides; Large VLDL; Lipoprotein lipase; Free fatty acids.